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Abstract
The BCH (BNIP2 and Cdc42GAP Homology) domain-containing protein Bmcc1/Prune2 is highly enriched in the brain and is
involved in the regulation of cytoskeleton dynamics and cell survival. However, the molecular mechanisms accounting for
these functions are poorly defined. Here, we have identified Bmcc1s, a novel isoform of Bmcc1 predominantly expressed in
the mouse brain. In primary cultures of astrocytes and neurons, Bmcc1s localized on intermediate filaments and
microtubules and interacted directly with MAP6/STOP, a microtubule-binding protein responsible for microtubule cold
stability. Bmcc1s overexpression inhibited MAP6-induced microtubule cold stability by displacing MAP6 away from
microtubules. It also resulted in the formation of membrane protrusions for which MAP6 was a necessary cofactor of
Bmcc1s. This study identifies Bmcc1s as a new MAP6 interacting protein able to modulate MAP6-induced microtubule cold
stability. Moreover, it illustrates a novel mechanism by which Bmcc1 regulates cell morphology.
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Introduction
The BCH (BNIP2 and Cdc42GAP Homology)-domain-con-
taining proteins have recently emerged as a new class of molecules
involved in the regulation of cell dynamics through the
engagement of specific Rho small GTPases. For instance, BNIP-
2 induces cell protrusions by targeting Cdc42 [1–3] and promotes
muscle differentiation [4]. p50RhoGAP modulates Rho and
Cdc42 activity and controls cell morphology and cell migration
[5]. BNIP-S targets RhoA and displaces p50RhoGAP, leading to
RhoA activation, cell rounding and apoptosis [6,7]. BP-GAP1
enhances RhoA activity, interacts with Cdc42 and Rac1, and
controls cell morphology and migration [8,9]. Recent works have
also suggested that the functions of BCH-containing molecules
could be more diverse. Indeed, BNIP-H (Caytaxin) interacts with
the kidney-type glutaminase to regulate glutamate production and
glutaminase trafficking [7], with the peptidyl-prolyl isomerase Pin1
to control neurite outgrowth [10] and with kinesin-1, an
intracellular transport protein [11].
BMCC1 (Bcl2, the adenovirus E1B 19 kDa interacting protein
2 and the Cdc42 GAP homology BCH motif-containing molecule
at the carboxy-terminal region 1), also called PRUNE2, is a large
molecule highly expressed in the brain as well as in spinal cord and
dorsal root ganglia [12–14]. Overexpression of one of its isoforms,
BNIP-XL (for BNIP-2 Extra Long), has been shown to promote
the formation of short membrane protrusions, to inhibit RhoA and
to suppress cell transformation initiated by Lbc, a RhoA-specific
guanine nucleotide exchange factor [15]. Thus, a putative role for
BMCC1 in the regulation of cytoskeleton dynamics as well as in
apoptosis has been suggested. Interestingly, the BMCC1 transcript
has been shown to be strongly upregulated in spontaneously
regressing neuroblastomas [12], as well as in the neurodevelop-
mental Rett syndrome [16].
BMCC1 encodes several isoforms whose expression pattern and
subcellular localization are unknown. Here, we have identified
Bmcc1s, a novel short isoform of Bmcc1 predominantly expressed
in the mouse brain. We show that Bmcc1s localizes on
intermediate filaments and microtubules in primary cultures of
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35488astrocytes and neurons, and interacts directly with MAP6 (aka
STOP), a microtubule-associated protein responsible for microtu-
bule cold stability [17,18]. Moreover, we demonstrate that Bmcc1s
overexpression inhibits microtubule stability through the displace-
ment of MAP6 away from microtubules, resulting in the formation
of membrane protrusions.
Results
Characterization of Bmcc1s, a novel brain Bmcc1 isoform
BMCC1 encodes several isoforms [12,13,15]. A compilation of
data from the literature and sequence databases is presented in
figure 1, figure S1 (mouse gene) and figure S2 (human gene). Both
human and mouse genes featured a comparable exon/intron
structure and encoded multiple transcript isoforms, generated by
alternative splicing and by the use of distinct promoters. In the
mouse, Bmcc1 cDNA variants encoded proteins containing either
the N-terminal (N-ter) or the C-terminal (C-ter) end of the
predicted full-length protein (up to 340 kDa) (Fig. S1). The
sequence of the latter category corresponded mainly to the BNIP-2
homology domain, including the BCH domain (encoded by exons
14 to 17), which could vary depending on alternative splicing of
exons 18, 19 or 20 (Fig. S1). Considering the numerous Bmcc1
isoforms, we aimed at defining those expressed in the mouse brain.
59 RACE PCR performed on total adult mouse brain RNAs,
starting from the 39 end of Bmcc1 39UTR (Material and methods
and Fig. 1, Fig. S1A), led to the amplification of a unique 3.9 kbp
product, which we named Bmcc1s for short Bmcc1 (EMBL
accession number FR69337). Two additional 59 Race PCR
experiments starting from exon 12 and from the 59 extremity of
exon 21 did not extend the cDNA further (Material and methods
and Fig. 1, Fig. S1A). Bmcc1s predicted open-reading frame
mainly corresponded to the C-ter variant AK038997 (Fig. S1). It
encoded a 323-amino acid predicted protein with a theoretical
molecular mass of 37 kDa, which was 99% identical to AK038997
and contained a full BNIP-2 homology domain (Fig. 1). To
evaluate the expression profile of Bmcc1s, we first performed RT-
PCR experiments on the 39 end of its 39UTR (Fig. 1), using total
RNA extracted from various mouse tissues (Fig. S3). Amplification
occurred mainly in the brain, demonstrating that Bmcc1s
expression is highly specific to this organ. To detect the cognate
endogenously synthesized Bmcc1s protein, we raised a rabbit
polyclonal antiserum directed against two peptides encoded by
exon 11 and 12, which are present in all C-ter Bmcc1 isoforms
(Material and methods and Fig. 1, Fig. S1). The specificity of this
serum was tested by preincubating it with immobilized in vitro
synthesized GST-Bmcc1s (Fig. S4, see Materials and Methods)
and by immunostaining and immunobloting of HeLa cells
transfected with a plasmid coding for Bmcc1s tagged with V5
(Material and Methods) (Fig. 2A). Both anti-V5 and anti-Bmcc1
antibodies revealed a band at the expected size of about 37 kDa,
as well as a higher band around 50 kDa which could result from
uncharacterized post-translational modifications of the protein
(Fig. 2A). The 50 kDa band was also detected in untransfected
HeLa cells, which endogenously express BMCC1 [12,13]. Since
one of the immunogenic peptides used to generate our antiserum
was fully conserved in human (Fig. S2), this band may represent
the endogenous BMCC1s protein. Finally, anti-Bmcc1 antibodies
strongly detected the V5 positive HeLa cells, and both signals
overlapped (Fig. 2A). Together, these results argued for the
specificity of our Bmcc1 antiserum. The expression profile of
Bmcc1s was next examined by Western blotting in various mouse
tissue lysates (Fig. 2B), as well as in lysates of primary astrocyte and
neuron cultures (Fig. 2C). In tissues, Bmcc1 antiserum recognized
various patterns of bands. In particular, several bands were
detected in brain extracts, demonstrating the expression of Bmcc1
isoforms longer than Bmcc1s. However, a 50 kDa band
corresponding to the higher band detected in Bmcc1s-V5
expressing HeLa cells appeared as the most represented Bmcc1
variant and was not detected in the other tested tissues (Fig. 2B).
The same major band was observed in the developing brain from
birth to adult stage (Fig. S5) and in primary cultures of astrocytes
and neurons (Fig. 2C). This Bmcc1 isoform should thus represent
Bmcc1s.
Bmcc1s localizes on microtubules and intermediate
filaments in neurons and astrocytes
Subcellular localization of endogenous Bmcc1s was analyzed in
primary cultures of DIV 7 astrocytes and DIV 7 neurons. In
immunofluorescence microscopy, Bmcc1s formed punctuate spots
aligned in a filamentous fashion in astrocytes (Fig. 3A) while it was
denser in neurons (Fig. 4A). Colabeling with a-tubulin demon-
strated a colocalization of Bmcc1s with microtubules (in neurons:
cell body 25620% (n=3); neurites 8069% (n=3); in astrocytes:
47613% (n=4)) (Figs. 3A, 4A). Incubation of both astrocytes and
neurons with nocodazole resulted in a partial depolymerization of
microtubules and a parallel displacement of a-tubulin and
Bmcc1s, strongly supporting the association of Bmcc1s with
microtubules (Figs. 3B, 4B). Colabeling experiments also revealed
that part of the Bmcc1s signal colocalized with GFAP (Glial
Fibrillary Acidic Protein), the astrocyte-specific intermediate
filament protein (57616% (n=4)) (Fig. 3C), and with NF-M, a
component of the intermediate filaments in neurons (cell body
19614% (n=3); neurites 64612% (n=3)) (Fig. 4C). Consistently,
immunoelectron transmission microscopy detected endogenous
Bmcc1s on cytoskeleton-type structures compatible with microtu-
bules and intermediate filaments (Figs. 3D, 4D). In order to further
explore the relationship between Bmcc1s and microtubules, we
next examined the possibility of a direct binding of Bmcc1s to
microtubules by standard microtubule binding in vitro assays
(Fig. 5). Bmcc1s remained in the soluble fraction and did not co-
sediment with taxol-stabilized microtubules. Thus, Bmcc1s
colocalizes with microtubules and intermediate filaments, but in
vitro it does not behave as a microtubule-binding protein.
Bmcc1s interacts with the microtubule-associated
protein MAP6
To further explore the functions of Bmcc1s, we searched for its
binding partners by performing GST pull-down assays and
matrix-assisted laser desorption/ionization time of flight
(MALDI-TOF) mass spectrometry. Whole adult mouse brain
lysates were incubated on either immobilized GST-Bmcc1s or on
GST alone expressed and purified from E. coli. As controls, GST-
Bmcc1s and GST were incubated with lysis buffer only. Bound
proteins were eluted and resolved by SDS-PAGE. Visualization by
Coomassie staining revealed a band around 120 kDa in the brain
lysate retained by GST-Bmcc1s which was not present in controls
(Fig. 6A). This band was subjected to trypsin-digestion followed by
MALDI-TOF analysis and was identified as the microtubule-
associated protein MAP6, also called STOP (Fig. 6C). MAP6
displays multiple isoforms which associate to microtubules and
induce their stabilization [18]. In particular, they protect
microtubules from depolymerization when cells are submitted to
cold [19]. Here, MAP6 peptides sorted by mass spectrometry
covered the N-terminal region of the neuronal MAP6 isoforms N-
STOP and E-STOP (Fig. 6C). We next probed a Western blot of
the eluates with the MAP6 polyclonal purified antibody 23N [19]
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35488Figure 1. Structure of Bmcc1s. (A) Schematic representation of mouse Bmcc1 gene. Exons are boxed, in black for the coding sequence and in
white for the 59 and 39 non-coding sequences. Primers for 59 RACE and RTPCR experiments are indicated by arrows under exons 11, 12 and 21. (B)
Schematic representation of mouse Bmcc1 transcript. (C) Schematic representation of Bmcc1s cDNA and protein. The BNIP2 homology and BCH
domains are indicated. Asterisks show the antigenic peptides used to generate the Bmcc1s antiserum.
doi:10.1371/journal.pone.0035488.g001
Figure 2. Immunodetection of Bmcc1s. (A) Immunoblot of Bmcc1s in lysates of HeLa cells transfected with a plasmid expressing Bmcc1s-V5.
Similar profiles were obtained using the Bmcc1 antiserum or anti-V5 antibodies. Note that the Bmcc1 antiserum recognized an endogenous protein
around 50 kDa (arrow) of the same size as Bmcc1s in untransfected HeLa cells. Immunostaining of HeLa cells transfected with a plasmid expressing
Bmcc1s-V5, using either the Bmcc1 antiserum or anti-V5 antibodies. The antiserum detected only the V5 positive cells, and both signals overlapped.
Scale bar: 100 mm (B) Immunoblot of endogenous Bmcc1 isoforms in mouse tissue lysates using Bmcc1 antiserum. GAPDH expression is shown as a
loading reference. As in HeLa cells expressing Bmcc1s-V5, the Bmcc1 antiserum detected a band around 50 kDa (arrow) in the brain lysate that
appeared specific to this tissue and was the most abundant among the Bmcc1 isoforms. (C) Immunoblot of endogenous Bmcc1 in primary cultures of
astrocyte and neuron lysates at DIV7, using Bmcc1 antiserum. As found in brain tissues, a major band around 50 kDa was detected (arrow).
doi:10.1371/journal.pone.0035488.g002
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buffer or in GST/brain lysate eluates, indicating the specificity of
the Bmcc1s-MAP6 interaction (Fig. 6B). Several MAP6 isoforms
were revealed in the GST-Bmcc1s/brain lysate eluate, namely the
neuronal isoforms N-STOP (120 kDa) and E-STOP (80 kDa), the
astrocyte isoform A-STOP (60 KDa) and a fibroblastic and
astroglial 48 kDa isoform [18,20]. In contrast, the main MAP6
fibroblast isoform F-STOP (42 kDa), also weakly expressed in
astrocytes and neurons, was not detected. To confirm that in vivo
MAP6 is a bona fide Bmcc1s-interacting partner, we immunopre-
cipitated endogenous MAP6 proteins from mouse brain lysates
(Fig. 6D). Western blot analysis of the precipitate revealed the
presence of Bmcc1s, supporting the fact that MAP6 and Bmcc1s
are part of the same physiological complex in the brain. A shorter
Bmcc1 isoform around 40 kDa was also co-immunoprecipitated
indicating the possible interaction of MAP6 with other Bmcc1
isoforms in the brain. To further explore the interaction between
Bmcc1s and MAP6, we next performed Bmcc1s GST pull-down
assays using in vitro purified MAP6 isoforms (Material and
methods). As shown in figure 6E, Bmcc1s specifically retained
the neuronal MAP6 isoforms N-STOP and E-STOP. In contrast,
in the same ionic conditions, the fibroblast MAP6 isoform F-
Figure 3. Subcellular localization of Bmcc1s in primary cultures of astrocyte. (A–C) Confocal section images of primary astrocytes
immunostained for endogenous Bmcc1s (green) and a-tubulin or GFAP (red). Merge images showed that Bmcc1s forms punctate spots mainly
distributed along a-tubulin stained microtubules (A) and partially colocalized with GFAP-positive intermediate filaments (C). Boxed regions in A
indicate the fields enlarged in each image. B. In nocodazole-treated primary astrocytes (10 mM, 1 h), Bmcc1s followed the disrupted a-tubulin
microtubular staining. (D) Immunogold labelling and electron mircroscopy analysis of primary astrocytes showed that Bmcc1s localized on
cytoskeleton-type structures compatible with microtubules (left) and intermediate filaments (right). Bars: 10 mm (A–C); 200 nm (D).
doi:10.1371/journal.pone.0035488.g003
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in agreement with these results, immunocytofluorescence exper-
iments on primary neurons showed that Bmcc1s partially
colocalized with endogeneous N-STOP (Fig. S6). Altogether,
these results identify Bmcc1s as a new ligand of astroglial and
neuronal MAP6 isoforms.
Bmcc1s inhibits microtubule cold stability
To explore the functional significance of Bmcc1s-MAP6
interaction, we next tested whether Bmcc1s could modulate
MAP6-induced microtubule cold stability. In vitro polymerized
microtubules at 37uC or subjected to cold were recovered by
sedimentation and analyzed by SDS-PAGE and coomassie
staining (Fig. 7A). At 4uC, almost no microtubules could be
recovered. In contrast, they were preserved at 4uC in presence of
N-STOP or F-STOP, demonstrating the microtubule-stabilizing
effect of MAP6. Adding increasing concentrations of GST-Bmcc1s
progressively lowered the level of microtubules in presence of N-
STOP. In contrast, in presence of F-STOP, with which it does not
interact, Bmcc1s had no effect, and neither did GST alone. Thus,
Bmcc1s inhibited the N-STOP-induced microtubule cold stability
in vitro without affecting that of F-STOP. We next assessed this
effect in cultured cells. Transfection of N-STOP in HeLa cells,
which are naturally devoid of MAP6, induces microtubule cold
stability [21]. HeLa cells stably transfected with GFP-N-STOP
(GFP-N-STOP HeLa) were transfected with a Bmcc1s-V5
expressing plasmid. Twenty-four hours following transfection,
cells were placed at 0uC for 45 min and microtubule resistance to
cold was assessed by a-tubulin immunostaining following free
tubulin extraction (Material and methods) (Fig. 7B). In Bmcc1s-V5
transfected GFP-N-STOP HeLa cells, V5 staining entirely
retracted to adopt a ball shape. In addition, a-tubulin staining
was no longer detectable, indicating a complete depolymerization
of microtubules compared to untransfected cells. We next tested
whether Bmcc1s could have the same effect on endogenous MAP6
Figure 4. Subcellular localization of Bmcc1s in primary neurons. (A–C) Confocal section images of primary neurons after 7 days of culture
immunostained for endogenous Bmcc1s (green) and a-tubulin or neurofilament subunit M (NF-M) (red). Merge images showed that Bmcc1s
colocalizes with a-tubulin (A) and NF-M (C) immunoreactivity signal. Boxed regions in A and C indicate the fields enlarged in each image. B. In
nocodazole-treated primary neurons (10 mM, 1 h), Bmcc1s followed the disrupted a-tubulin microtubular staining. (D) Immunogold labeling and
electron microscopy analysis of primary neurons showed that Bmcc1s localized on cytoskeleton-type structures compatible with microtubules (left)
and intermediate filaments (right). Bars: 10 mm (A–C); 100 nm (D).
doi:10.1371/journal.pone.0035488.g004
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transfected with Bmcc1-V5 and cold-treated in the next 24 h.
After cold treatment, little or no a-tubulin staining could be seen in
Bmcc1s-V5 expressing astrocytes. In addition, V5 staining entirely
retracted to adopt a ball shape, as already observed in HeLa cells
(Fig. 7C). Finally, Bmcc1s-V5-transfected neurons exposed to cold
also lost a-tubulin staining (Fig. 7D). Altogether these observations
indicate that Bmcc1s overexpression inhibits MAP6-induced
microtubule cold stability.
Bmcc1s displaces the neuronal MAP6 isoform N-STOP
away from microtubules and induces the formation of
membrane protrusions
By which mechanism does Bmcc1s inhibit the microtubule
cold-stabilizing effect of MAP6? Since this phenomenon depends
on the direct interaction of MAP6 with microtubules [22], we
examined the subcellular distribution of N-STOP in GFP-N-
STOP HeLa cells transfected or not with the Bmcc1s-V5
expressing plasmid. In GFP-N-STOP HeLa cells, N-STOP
displayed a fibrillar aspect reminiscent of its association with
microtubules (Fig. 8A) [18]. Accumulation of N-STOP staining in
a perinuclear area possibly corresponding to the Golgi apparatus
was also detected as previously described [23]. When Bmcc1s-V5
was transfected in these cells, the N-STOP labeling changed
dramatically (Fig. 8A). It appeared brighter and part of it
completely lost its cytoskeleton-type distribution, being more
diffuse and concentrated at the cell periphery. Surprisingly, in
contrast to untransfected GFP-N-STOP HeLa cells (Fig. 8A) or
HeLa cells transfected only with Bmcc1s-V5 (Fig. 8B), GFP-N-
STOP HeLa cells expressing Bmcc1s-V5 showed numerous
membrane protrusions sprouting up in all directions and densely
labeled for both V5 and N-STOP (Fig. 8A). In order to observe in
parallel N-STOP and the actin and microtubule cytoskeletons,
HeLa cells stably transfected with the Bmcc1s-V5 expressing
plasmid (Bmcc1s-V5 HeLa) were transfected with the GFP-N-
STOP expressing plasmid (Fig. 8C). As demonstrated by double
immunostaining of a-tubulin and N-STOP, part of the N-STOP
staining no longer localized on microtubules. Instead, as observed
above (Fig. 8A), it was diffuse and more concentrated in actin-rich
phalloidin-labeled areas at the cell periphery and in membrane
protrusions (Fig. 8C). Thus, Bmcc1s relocates N-STOP away from
microtubules. In addition, in presence of both Bmcc1s and N-
STOP, numerous membrane protrusions are formed.
Morphological effects are induced by Bmcc1s together
with MAP6
By which mechanism do Bmcc1s and MAP6 induce the
formation of membrane protrusions? HeLa cells expressing only
Bmcc1s-V5 or N-STOP did not show any obvious morphological
change compared to HeLa expressing both proteins, indicating
that the expression of one or the other is not sufficient to induce
the formation of membrane protrusions. We therefore tested the
effect of Bmcc1s transfection in cells expressing MAP6 endoge-
nously. Primary astrocytes at DIV7 and neurons at DIV1 were
transfected with the Bmcc1s-V5 expression plasmid. Cell mor-
phology was analyzed 24 h after transfection. In agreement with
our previous observations in HeLa cells expressing both N-STOP
and Bmcc1s-V5 (Fig. 8A, 8C), in primary astrocytes Bmcc1s-V5
transfection resulted in the formation of long membrane
protrusions sprouting out from the transfected cells in all
directions, without obvious change in the pattern of actin stress
fibers (Fig. 9A). No protrusion could be seen in cells transfected
with a GFP-only expressing plasmid (Fig. 9A). Next, cell
morphology as well as neurite length and number were compared
in Bmcc1s-V5 and GFP-transfected primary neurons (Material
and methods) (Fig. 9B). Compared to GFP, Bmcc1s-V5-expressing
neurons often showed a very complex morphology, with an
increase in the number of ramifications (Fig. 9B). In GFP-
expressing neurons, the length of the longest neurite was
58.1644.8 mm (n=97), and the number of extensions starting
from the soma was 3.061.4. In Bmcc1-V5 expressing neurons, the
longest neurite reached 82.2649.4 mm (n=56), and the number
of cell extensions was 4.462.5. These results indicated that
Bmcc1s-V5 significantly increased neurite length (p-value,0.001)
and number (p-value,0.0001). In contrast, actin labeling was
comparable in GFP and Bmcc1s-V5-expressing neurons. We
finally compared the morphology of Bmcc1s-V5 and GFP-
transfected primary neurons prepared from MAP6 deficient mice
[17] (Fig. 9B). Under Bmcc1s-V5 expression, the longest neurite
reached 41.8626.7 mm (n=42), and the number of cell extensions
was 3.361.8, whereas in GFP-transfected primary Map6
2/2
neurons, the longest neurite reached 40.2629.3 mm (n=88), and
the number of cell extensions was 2.661.4. Thus, in Map6
2/2
primary neurons, Bmcc1-V5 transfection had no significant effect
on neurite length and number (p-value.0.01). Altogether, these
results suggest that Bmcc1s requires MAP6 as a cofactor to induce
membrane protrusions.
Discussion
In this study, we characterize Bmcc1s, a novel isoform of the
BCH domain-containing molecule Bmcc1, predominantly ex-
pressed in the mouse brain. To date, BCH-proteins have been
mostly studied for their capacity to bind and regulate the activity
of Rho-small GTPases [1–9], with the exception of BNIP-H (or
Figure 5. Microtubule Co-sedimentation assays. Taxol stabilized
microtubules were incubated with or without GST-Bmcc1s. The samples
were then sedimented through a 60% glycerol cushion. The superna-
tants (S) and pellets (P) were separated by SDS-PAGE and stained with
Coomassie Blue. Tubulin (50 kDa) was mostly present in the pellet
fraction with or without Bmcc1s, while Bmcc1s was only detectable in
the supernatant.
doi:10.1371/journal.pone.0035488.g005
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[7], the peptidyl-prolyl isomerase Pin1 [10] and kinesin-1 [11].
Here we show that Bmcc1s interacts directly with MAP6,
indicating that the functions of BCH-containing molecules are
more diverse than initially expected. Bmcc1s binds to neuronal
MAP6 isoforms N-STOP and E-STOP, astroglial MAP6 A-STOP
and a 48 kDa astroglial and fibroblastic MAP6 isoform, but not to
the fibroblastic F-STOP. Direct binding experiments with A-
STOP and the 48 kDa isoforms were not performed since their
sequences are not fully characterized. Nevertheless, our results
indicated that interaction between MAP6 and Bmcc1s did not
occur in domains shared by the neuronal MAP6 isoforms and F-
STOP, i.e. all the central microtubule-stabilizing Mc modules and
the microtubule-stabilizing Mn3 [18].
Bmcc1s localized on intermediate filaments and microtubules.
Accordingly, our mass spectrometry analysis of the proteins pulled
Figure 6. Bmcc1s interacts with MAP6. (A) GST-Bmcc1s or GST immobilized on glutathione sepharose beads were incubated with either a lysis
buffer or a mouse brain lysate. After elution, bound proteins were resolved on SDS-PAGE in parallel with the mouse brain lysate, and visualized by
Coomassie staining. A unique band (square) was analyzed by MALDI-TOF, where MAP6 was identified. (B) The presence of MAP6 and the specificity of
its interaction with Bmcc1s were confirmed by Western blot of the GST eluates with 23N, a polyclonal anti-MAP6 antibody. Several bands
corresponding to the neuronal MAP6 isoforms N-STOP (120 kDa) and E-STOP (80 kDa), the astrocyte MAP6 isoform A-STOP (60 KDa) and a 48 kDa
isoform described in total brain protein extracts were revealed. (C) MALDI-TOF analysis revealed the presence of 4 peptides (in red) corresponding to
MAP6. The microtubule-stabilizing modules Mn1, Mn2 and Mc1 of MAP6 are underlined. (D) Co-immunoprecipitation of MAP6 and Bmcc1s was
performed using the 175 monoclonal anti-MAP6 antibody (IP+aMAP6), or no antibody (IP-aMAP6) as control, on mouse brain lysates. Precipitates
were analyzed by Western blotting with Bmcc1 antiserum, in parallel with the mouse brain lysate. Bmcc1s was co-immunoprecipitated with MAP6. (E)
Pull-down experiments of purified MAP6 isoforms: neuronal, N- and E-STOP and the fibroblast F-STOP, by purified glutathione-S-transferase (GST)-
Bmcc1s or GST. Bound proteins were resolved on SDS-PAGE and Coomassie stained. N- and E-STOP were specifically retained by GST-Bmcc1s.
doi:10.1371/journal.pone.0035488.g006
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microtubule-associated protein MAP6 but also with the medium-
sized neurofilament protein [24] (data not shown). The association
of intermediate filaments to microtubules specifically involves
detyrosinated microtubules (Glu-MTs) [25,26], a subset of stable
microtubules enriched in MAP6 [19]. Furthermore, MAP6 has
been shown to co-aggregate with intermediate filaments in
neurons [27]. Thus, interaction of Bmcc1s with MAP6 and its
colocalization with microtubules and intermediate filaments may
indicate a role for Bmcc1s in the cross-talk between both
cytoskeletons.
The MAP6-induced microtubule protective effect operates
through its direct interaction with microtubules [22]. Here, we
showed that Bmcc1s inhibited the microtubule cold resistance and
Figure 7. Bmcc1s inhibits the MAP6-induced microtubule cold stability. (A) Inhibition of N-STOP-induced microtubule cold stability by
Bmcc1s in vitro. Microtubules polymerized at 37uC and subjected to cold were recovered by sedimentation and analyzed by SDS-PAGE and coomassie
staining. The observed 50 kDa band corresponds to polymerized tubulin. At 4uC, almost no microtubules could be recovered. In contrast, they were
preserved at 4uC in presence of N-STOP or F-STOP. Adding increasing concentrations of GST-Bmcc1s progressively decreased the level of
microtubules in presence of N-STOP, but not of F-STOP. In contrast, GST alone had no effect. Numbers indicate the final concentration of the proteins
in micromolar in the depolymerization reaction mix. Concentration of tubulin was 30 mM. (B,C,D) Confocal microscopy image projections of cells
transiently transfected with a plasmid expressing Bmcc1s-V5. Twenty-four hours after transfection, cells were exposed to 0uC for 45 minutes.
Following free tubulin extraction by cell permeabilization, cells were fixed and double-stained for a-tubulin antibody (red), and V5 (green). Nuclei
were stained with DAPI (blue). (B) HeLa cells stably transfected with GFP-N-STOP; (C) Primary culture of astrocytes; (D) Primary culture of neurons. In
Bmcc1s-V5 transfected cells (green), a-tubulin staining was almost gone and V5 staining either retracted in a ball shape in the case of GFP-N-STOP
HeLa cells and astrocytes, or filled the cell body in neurons. Bars: 10 mm.
doi:10.1371/journal.pone.0035488.g007
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35488Figure 8. Bmcc1s overexpression displaces MAP6 away from the microtubules and induces the formation of membrane
protrusions. (A) HeLa cells stably transfected with GFP-N-STOP (GFP-N-STOP HeLa) transiently transfected with an expression plasmid for Bmcc1s-
V5. Twenty-four hours after transfection, cells were fixed and double-stained for N-STOP using the 23N polyclonal MAP6 antibody (green) and for
Bmcc1s-V5 using a monoclonal anti V5 antibody (red). In untransfected GFP-N-STOP HeLa, N-STOP staining showed a microtubule-like pattern. The
Golgi apparatus was also labeled (asterisks). Insert (a) is an enlargement of the squared region showing N-STOP staining in more detail. In the Bmcc1s-
V5 GFP-N-STOP HeLa transfected cell (white arrows), N-STOP labeling became brighter, no longer featuring its typical microtubule-type distribution,
and numerous membrane protrusions (white arrowheads) labeled for both V5 and N-STOP were seen. Insert (b) is an enlargement of the Bmcc1s-V5
GFP-N-STOP HeLa transfected cell. (B) Confocal microscopy images of HeLa cells transiently transfected with an expression plasmid for Bmcc1s-V5.
Twenty-four hours after transfection, cells were fixed and double-stained for Bmcc1s-V5 using a monoclonal anti V5 antibody (green) and for F-actin
using TRITC-conjugated phalloidin (red). (C) Confocal microscopy images of a Bmcc1s-V5 stably transfected HeLa cell (Bmcc1s-V5 HeLa) transiently
transfected with an expression plasmid for GFP-N-STOP. Twenty-four hours after transfection, cells were fixed and stained for N-STOP using the 23N
polyclonal anti-MAP6 antibody (green), for microtubules using a a-tubulin antibody (blue), and for F-actin using TRITC-conjugated phalloidin (red).
Merge images show that N-STOP partially loses its microtubular staining, being more diffuse in the cell, and located in actin-rich membrane
protrusions (white arrowheads). Bars: 10 mm.
doi:10.1371/journal.pone.0035488.g008
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PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e35488moved N-STOP away from microtubules. Microtubules consis-
tently lost their resistance to the cold. This effect was also observed
in primary astrocytes and neurons transfected with Bmcc1s,
suggesting that endogenous MAP6 no longer interacted with
microtubules. Thus, our results strongly suggest that Bmcc1s, by its
ability to associate with MAP6, regulates MAP6-microtubules
interaction and disrupts it when increased, leading to the loss of
cold resistance. Therefore, Bmcc1s is a new molecular partner of
MAP6 with the capacity to influence its microtubule interaction
and protective functions.
Transfection of Bmcc1s also resulted in numerous membrane
protrusions in astrocytes as well as in neurons, in which the length
of the principal neurites was also increased. In neurons, these
effects were abolished in absence of MAP6. In HeLa cells, the
protruding effect was not observed unless Bmcc1s was co-
expressed with N-STOP. Altogether, these results strongly suggest
the requirement of both MAP6 and Bmcc1s to induce morpho-
logical alterations. What is the mechanism involved? In HeLa cells
coexpressing Bmcc1s and N-STOP, N-STOP appeared partially
relocated from the microtubules, in particular in actin-rich
protrusions. Interestingly, MAP6 not only interacts with microtu-
bules but with polymerized actin in vitro, suggesting that it may
play a role in actin cytoskeleton dynamics [28]. Thus, an attractive
hypothesis would be that, in the presence of high level of Bmcc1s,
MAP6 dissociates from microtubules and binds to actin. In
differentiating neurons, N-STOP when phosphorylated was shown
to colocalize with actin rich areas in spikes and at branching
points, but not with microtubules [28]. Thus, we tested whether
such mechanism could occur under Bmcc1s overexpression in
protein extracts prepared from Bmcc1s and N-STOP transfected
HeLa cells. The molecular weight of N-STOP did not shift in
presence of Bmcc1s (data not shown), suggesting that Bmcc1s does
not influence the phosphorylation status of N-STOP. In vitro, the
effect of Bmcc1s on the N-STOP microtubule stabilizing effect
appeared to be dose-dependent, thus an alternative hypothesis
would be that increased levels of Bmcc1s reduce the level of MAP6
available for microtubule interaction, favoring its link to actin. The
question now arises as to how MAP6 could possibly act on actin
dynamics to induce the formation of membrane protrusions,
which is still an open issue.
In conclusion, Bmcc1s is a novel Bmcc1 isoform predominantly
expressed in the brain and present in astrocytes and neurons. It
localizes on intermediate filaments and microtubules and directly
interacts with the microtubule-associated protein MAP6. Overex-
pression of Bmcc1s displaces MAP6 from microtubules, inhibiting
its protective effect to cold and affecting cell morphology. The
transcription of BMCC1 has been found to be strongly upregulated
in the neurodegenerative Rett syndrome [16]. Thus, the alteration
of astroglial and neuronal cell morphology and the modulation of
MAP6 functions, which result from Bmcc1s upregulation, could
represent molecular and cellular mechanisms involved in this
pathology.
Materials and Methods
Animal experimentation
In compliance with the European Community Council
Directive of November 24, 1986 (86/609/EEC), research
involving animals has been authorized by the Direction De ´parte-
mentale de la Protection des Populations, Pre ´fecture de l’Ise `re,
France (permit nu38 09 18). Every effort has been made to
minimize the number of animals used and their suffering. This
study has been approved by the local ethics committee of
Grenoble Institut des Neurosciences.
Data deposition
The sequence of Bmcc1s reported in this paper has been
deposited in the EMBL/GenBank/DDBJ databases: accession
number FR69337.
Antibodies
Polyclonal antibodies against a mixture of two synthetic peptides
of mouse Bmcc1s were raised in rabbit (Covalab). Peptide
sequences were: (24–33) SLDLNGSHPR, and (101–113) SIPEY-
TAEEERED. Numbering refers to EMBL accession number
FR69337. To test the specificity of the antibodies, 1 ml of rabbit
serum was incubated overnight at 4uC with in vitro synthesized
GST-Bmcc1s bound to glutathione-sepharose beads. Eluates were
used to probe Western-blots of mouse brain protein extracts (data
not shown). Primary antibodies used were: Anti-MAP6 polyclonal
23N [19] (dilution 1:1000) and Monoclonal 175 [29], polyclonal
and monoclonal anti-V5 (Sigma-Aldrich) (dilution 1:500), mono-
clonal anti a-tubulin (Sigma-Aldrich) (dilution 1:1000), polyclonal
anti-RhoA (Santa Cruz Biotechnology) (dilution 1:1000), horse-
radish-peroxidase-conjugated monoclonal anti-GAPDH (Sigma)
(dilution 1:2500). Monoclonal antibody M20 against NF-M was
kindly provided by Dr Beat M. Riederer (Hornung et al., 1999)
(dilution 1:10). Secondary antibodies used were: Alexa-conjugated
goat anti-mouse and anti-rabbit IgGs (Molecular probes) (dilution
1:2000), Horseradish-peroxidase-conjugated goat anti-mouse and
anti-rabbit antibodies (Amersham) (dilution 1:2500).
59 RACE PCR RT-PCR and cloning
Elongation of Bmcc1s cDNA 59 end was performed using an
adult mouse brain cDNA library generated by the Marathon
method (Clontech). The reverse oligonucleotides used for the
specific amplification of Bmcc1 were: (first experiment) (3971–
3990 in exon 21) 59-AGGGCTGTGCAGAACCATGA -39,
(second experiment) (398–422 in exons 11 and 12) 59-
TGGCCGTGGGATCTTCATGGTTAGT -39, and (third ex-
periment) (1185–1209 in exon 21) 59-GTGGAGATGTCAC-
CATCCCTGTTGC-39. Elongation time was 5 min, using the
expand High fidelity Taq polymerase (Roche). PCR products were
cloned into pCR2.1-TOPO (Invitrogen) and sequenced. For RT-
PCR, total RNA was extracted from adult mouse tissues using the
RNeasy lipid tissue kit (Qiagen). Reverse transcription was
performed on 1 mg of total RNA using Superscript II reverse
Figure 9. Morphological changes induced by Bmcc1s overexpression requires MAP6. Confocal microscopy image projections of cells
transfected with a Bmcc1s-V5 or GFP expressing plasmid, and stained for V5 (green) and F-actin (detected with TRITC-conjugated phalloidin in red).
Cells were fixed 24 h after transfection. (A) primary astrocytes; (B) primary neurons. The morphology of GFP-expressing cells (green) was unchanged
compared to untransfected cells. In contrast, Bmcc1s-V5-expressing astrocytes and neurons developed numerous membrane protrusions (white
arrowheads). Images in B illustrate representative confocal projections of the effect of Bmcc1s-V5 on neuritic growth and number in wild-type
neurons. The whole Bmcc1s-V5 transfected neuron is shown in the insert. Histograms present means 6 sd of the length of the longest neurite and of
the number of neurites. *** p-value,0.0001 ** p-value,0.001. ns, not significant for 3 independent experiments using the two sample independent
t-test. In neurons, length of the longest neurite, and number of neurites (or cell extensions starting from the soma) were significantly increased by
Bmcc1s-V5 transfection, but not in MAP6-deleted neurons. Bars: 10 mm.
doi:10.1371/journal.pone.0035488.g009
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primer (first experiment) (3971–3990 in exon 21) and the upstream
forward primer (3895–3950) 59-CCCCTAGGGCATACC-
GATGA-39. Control Hprt amplification was performed using
the following primers: Hprt.f 59 GTTGGATACAGGCCA-
GACTTTGTTG 39; Hprt.r 59 GATTCAACTTGCGCT-
CATCTTAGGC 39. Expression construct for Bmcc1s was
performed by RT-PCR on adult mouse brain mRNA using the
Superscript II reverse transcriptase (Invitrogen) and the LA-Taq
polymerase (Takara), with the following primers: (146–170 in exon
10) 59-GGAATGGATATCCACTTCGAGGAGG-39 and (1093–
1117 in exon 21) 59-CGGCTTCTCCTTCAGCTTCATGTCA-
39. Amplification product was cloned into pcDNA3.1/V5-His-
TOPO (Invitrogen). glutathioneS-transferase (GST)-Bmcc1s was
cloned in pGEX-4T1 (Amersham). For this construct, Bmcc1s was
amplified using primers containing EcoR I or Sal I restriction sites
(in italics): (149–163 in exon 10 underlined) 59-GGGAATTCATG-
GATATCCACTTC_39 and (1106–1121 in exon 21) 59-
GGGTCGACGCTACGGCTTCTCCTT-39. Each construct was
verified by sequencing on both strands. The pSG5-N-STOP
expressing plasmid carried rat N-STOP cDNA into the Bgl II site
of pEGFP-C1 (Clontech) [21]. pEGFP-N-STOP plasmid was
generated by subcloning the Bgl II fragment of pSG5-N-STOP.
All numberings for primers refer to EMBL accession number
FR69337.
Protein extraction from mouse tissues and Western
blotting
Adult mouse tissues were dissected and reduced in powder at
280uC, immediately dissolved in PBS with 2% SDS, and 16
EDTA-free Complete Protease Inhibitor (Roche). Lysates were
sonicated twice at 10 Hz (Vibra cell VCX130) and centrifuged
20 min at 10000 g at 4uC. Supernatants were boiled in 56
Laemmli loading buffer. Protein content was measured using the
Pierce 660 nm protein assay reagent (Thermo scientific). Equal
amounts of proteins were separated by denaturing electrophoresis
in NuPAGE 3–8% Tris acetate gradient gel (Invitrogen),
electrotransfered to nitrocellulose membranes, first analyzed using
the Bmcc1 antiserum and HRP-congugated rabbit antibodies, and
then using a GAPDH-HRP coupled antibody. HRP activity was
visualized by ECL using Western Lightning plus enhanced
chemoluminescence system (Perkin Elmer). Chemoluminescence
imaging was performed on a LAS4000 (Fujifilm). GAPDH
expression was used as a loading reference.
Cell culture, transfection and drug treatments
Primary cortical neurons were prepared at embryonic day 15 as
previously described [30]. Primary cultures of cortical astrocytes
were prepared at post-natal day 2 as previously described [31].
HeLa cells (ATCC CCL-2) were grown in Dulbecco’s-modified
Eagle medium (DMEM; Invitrogen) supplemented with 10% fetal
calf serum, in 5% CO2 at 37uC. Stable transfectants for pEGFP-
N-STOP were selected with 500 mg/ml G418 during 15 days.
After 7 days of culture without G418, cells were then maintained
with 250 mg/ml G418 and FACS-sorted. Stable transfectants for
Bmcc1s-V5 were selected by adding 500 mg/ml G418. Transient
transfections were carried out on HeLa or DIV 7 primary
astrocytes with Lipofectamine 2000 according to the manufactur-
er’s instructions (Invitrogen). Primary Neurons were transfected at
DIV1. In this case, cells were incubated only 30 min with the
lipofectamine plasmid mix and returned to their initial culture
medium. Estimation of the neurite length and number was done
24 h after transfection using ImageJ software. Statistical analysis of
the results was done using the T-test. Three independent
experiments were performed. For the microtubule cold stability
analysis, cells were exposed 45 min to the cold on ice,
permeabilized in lysis buffer (30 mM Pipes, 1 mM EGTA,
1 mM MgCl2, 10% glycerol, 1% Triton X-100, pH 6.75) for
1 min and processed for immunofluorescence [23]. Control
experiments were performed using the pmaxGFP plasmid (Lonza).
Microtubule depolymerizing treatment was performed using
10 mM Nocodazole for 1 h at 37uC.
Immunocytofluorescence
Cells were grown on coverslips, fixed in 4% phosphate-buffered
(PBS) paraformaldehyde (PFA) for 10 min at room temperature,
and processed for immunofluorescence as described [32]. See the
‘‘antibodies’’ section for the dilutions of the various antibodies.
Fluorescence images were taken in a SP5 confocal microscope
(Leica). F-actin was detected with TRITC-conjugated phalloidin
(Sigma). Colocalization of Bmcc1s with a-tubulin, GFAP and NF-
M was estimated using the ImageJ software.
Immnunoelectron microscopy
Astrocytes were fixed with 4% (w/v) PFA and 0.1%
glutaraldehyde (Polysciences, Inc, Warrington) in PBS. After
being washed in PBS, the cells were treated with ammonium
chloride (0.13 g/50 ml of PBS) for 30 min at 4uC, gradually
dehydrated in ethanol, and embedded in lowicryl Hm20
(Polysciences) in an AFS REICHERT (Leica) after a progressive
lowering of temperature. After polymerisation under UV light at
45uC below zero for 48 h, pale yellow sections were incubated for
30 min in goat gold conjugate-blocking solution (Aurion, Wagen-
ingen, Netherlands). The sections were washed (three times for
5 min each) in PBS 0.1% bovine serum albumin-c (Aurion).
Sections were subsequently incubated overnight at 4uC in the
same buffer with Bmcc1 antiserum. After extensive washes (six
times for 5 min each), the sections were incubated 1 h at room
temperature in 20 nm gold-conjugated secondary antibodies
against rabbit IgG (1:50, British Biocell International, Cardiff,
UK), washed (six times for 5 min each) in the incubation buffer,
and then in PBS (two times for 5 min), followed by a 5 min
fixation in 2% glutaraldehyde in PBS. After a wash of 5 min in
PBS and six washes of 2 min in distilled water, sections were
counterstained with uranyl acetate and lead citrate for inspection
with a Philips tecnai 12 electron microscope (FEI the Eindhoven,
The Netherlands). Primary neurons (11 DIV) were plated on
thermanox coverslips (Nunc, Inc. Naperville, IL) and frozen in a
Leica HPM 100 apparatus under a pressure of 2100 bar. After
freezing, samples were rapidly transferred to liquid nitrogen.
Cryosubstitution and embedding of the cells were then performed
in a AFS 2 apparatus (Leica) in anhydrous methanol with 1,5%
uranyl acetate at 290uc for 40 h with one change of solution.
After extensive washes in anhydrous methanol, cells were slowly
warmed to 245uC( 5 uC/h) and gradually embedded in lowicryl
Hm20 (Polysciences). After polymerisation under a UV light at
245uC during 48 h, coverslips were warmed to room tempera-
ture, mounted on resin block and cut in parallel to the cell plan.
The coverslips were completely removed with the glass knife until
reaching the cells. Thin sections were cut using a Leica ultracut E
and incubated 30 min in goat gold conjugates blocking solution
(Aurion). Sections were then washed three times for 5 min in PBS
with 0.1% bovine serum albumin-c (Aurion), and subsequently
incubated overnight at 4uC in the same buffer with the Bmcc1
antiserum (1:200). After six washes (5 min each), sections were
incubated 1 h at room temperature in 10 nm gold-conjugated
secondary antibodies against rabbit IgG (1:50, British Biocell
International) and washed six times 5 min in the incubation buffer,
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After a 5 min PBS wash and six washes of 2 min in distilled water,
sections were counterstained with uranyl acetate and lead citrate
for inspection with a Philips tecnai 12 electron microscope (FEI
the Eindhoven, The Netherlands).
Sedimentation of Bmcc1s with Microtubules
All proteins were preclarified at 150,000 g for 15 min in a TL-
100 Ultracentrifuge (Beckman) at 4uC before the experiment
started. Microtubule-binding assay was performed as previously
described, using 40 mg taxol-stabilized microtubules (4 mM) as
substrates and 1 to 4.5 mg of purified GST-Bmcc1s [33].
In vitro effect of Bmcc1s on microtubule stability
Microtubules were polymerized in vitro from bovine brain tubulin
(60 mM) in 2 ml of PEM (Pipes 100 mM pH6.75, EGTA1 mM,
MgCl2 1 mM) containing 1 mM GTP at 37uC. After 45 min,
microtubules were either preserved by dilution in 20 ml of 60%
sucrose/PEM solution at 37uC or diluted with one volume (2 ml) of ice-
cold PEM-T solution (PEM+0.1% Tween 20) containing 2 mMo fN -
STOP or F-STOP proteins alone or mixed with either 4, 10, 20,
40 mMo fG S T - B m c c 1 so r4 0mM of GST and incubated for 30 min
on ice. Reaction mixes were then diluted with 20 mlo f3 7 uCs o l u t i o no f
60% sucrose in PEM, loaded on warm 60% sucrose in PEM cushions
(80 ml) and centrifuged at 200 000 g for 30 min at 37uC. Pellets were
briefly washed with 300 ml of PEM solution at 37uC, re-suspended in
Laemmli buffer and analyzed by SDS-PAGE and coomassie staining.
Identification of Bmcc1s-binding proteins
Adult mouse brains were homogenised in binding buffer (PBS
with 5% glycerol, 5 mM MgCl2, 0.1% Triton X-100, and 16
EDTA-free Complete Protease Inhibitor (Roche)) with a Dounce
tissue grinder. Lysates were sonicated twice at 10 Hz (Vibra cell
VCX130). Triton X-100 concentration was adjusted to 1% and
lysates were incubated 1 h at 4uC. After 20-min centrifugation at
10000 g at 4uC, protein content of the cleared lysates was
measured using the BCA protein assay (Thermo scientific). 500 mg
of proteins were incubated with GST-Bmcc1s fusion protein,
bound to glutathione-sepharose beads overnight at 4uC. After five
washes with binding buffer containing 150 mM NaCl, proteins
were boiled in 56 Laemmli loading buffer, separated by
denaturing electrophoresis in NuPAGE 4–12% SDS-polyacryl-
amide gradient gel (Invitrogen), and visualized by Coomassie
staining (BioRad). For mass spectrometry (MS) analyses, gel slices
were reduced, alkylated, and subjected to digestion with trypsin
(Roche) as previously described [34]. The extracted peptides were
dried and resolubilized in solvent A (95:5 water/acetonitrile in
0.1% [wt/v] formic acid). The total digestion product of a gel slice
was used for two liquid chromatography-tandem MS (LC-MS/
MS) analyses (1/5 and 4/5). The extracted peptides were
concentrated and separated on an HPLC system (Ultimate
3000; Dionex), coupled to the nano-electrospray ionization
interface of a mass spectrometer (QSTAR Elite; Applied
Biosystems) using a PicoTip emitter (10 mm in diameter; New
Objectives). HPLC mobile phases contained solvent A and solvent
B (20:80 water/acetonitrile in 0.085% [wt/v] formic acid). Bound
peptides were eluted with a gradient of 5–50% of solvent B.
Information-dependent acquisition was used to acquire MS/MS
data, with the experiments designed so that the three most
abundant peptides were subjected to collision-induced dissocia-
tion, using nitrogen as collision gas. Data from the information-
dependent acquisition experiments were searched twice using
MASCOT (Matrix Science) and PHENYX (Geneva Bioinfor-
matics) software on the NCBI nr Mus musculus database (National
Library of Medicine, Bethesda, 2009 07 03, 143362 protein
entries). All data were validated using myProMS [35].
Co-immunoprecipitation
Adult mouse brains were homogenized in RIPA lysis buffer
(50 mM TrisHCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 16 EDTA-free Complete
Protease Inhibitor (Roche)) with a Dounce tissue grinder. After
20 min centrifugation at 10000 g at 4uC, the lysate was precleared
with protein G sepharose (GE Healthcare) and protein content
was measured using the BCA protein assay (Thermo scientific).
5 ml of purified monoclonal 175 anti-MAP6 antibody was added to
500 mg of proteins and incubated at 4uC overnight. Immunocom-
plexes were captured by adding protein G sepharose for 1 hour at
4uC. After five washes with lysis buffer, beads were resuspended
and boiled in 56Laemmli loading buffer to release immunopre-
cipitates. Samples were separated by denaturing electrophoresis in
NuPAGE 4–12% SDS-polyacrylamide gradient gel (Invitrogen),
electrotransfered on nitrocellulose membranes, and analysed by
Western blotting with Bmcc1 antiserum and HRP-congugated
rabbit antibodies, using Western Lightning plus enhanced
chemoluminescence system (Perkin Elmer).
In vitro Bmcc1s-MAP6 interaction
MAP6 isoforms were expressed as N-terminal His-tagged
proteins in High-five insect cells. The F-STOP protein was
successively purified on anion-exchange Q-sepharose, Nickel-
NTA and calmodulin-agarose columns. The N-STOP protein was
purified by affinity first on a Ni-NTA column and then on a
column carrying the monoclonal 175 antibody. N-STOP was
eluted using the corresponding antigenic peptide. Regarding E-
STOP, affinity purification on Ni-NTA beads was sufficient to
obtain a protein with a high degree of purity. GST and GST-
Bmcc1s were expressed in E. coli and purified on glutathione-
agarose beads according to the manufacturer’s instructions. All the
proteins were extensively dialysed against PEM buffer (PIPES
100 mM pH6.6, EGTA 1 mM, MgCl2 1 mM). For GST pull-
down assays, 10 ml of glutathione-agarose beads were mixed with
either 2 mg of GST-BMCCsh1 or 4 mg of GST and 1.5 mg of one
of the purified STOP isoforms. After 2 h incubation at 4uCi n
300 ml of incubation buffer (PEM buffer plus 50 mM KCl, 0.05%
Triton-X100 and 1 mM DTT), the beads were sedimented at
300 g for 30 seconds, washed three times with 500 mlo f
incubation buffer and resuspended in Laemmli buffer. Samples
were separated on a 12.5% SDS-PAGE and Coomassie stained.
Supporting Information
Figure S1 Mouse Bmcc1/Prune2 gene, transcripts and
proteins. (A) Schematic representation of mouse Bmcc1 gene. All
exons and introns are at scale, unless indicated. Insert at exons 7a/
7b indicates the orthologous exon 4 of the human PCA3 gene on
the opposite strand, which overlaps with exon 7a. A & B. Exons
are boxed, in black for the coding sequence and in white for the 59
and 39 non-coding sequences. Alternative start and stop codons
are indicated. (B) Schematic representation of mouse Bmcc1
transcripts. Scale is as in A, and transcripts are given with their
accession number, size, library type, and exon composition. Solid
bar under exon 21 indicates DNA arrays probe set. Primers for 59
RACE experiments are indicated by arrows under exons 11/12
and 21. Dashes indicate reading frames that are still open. (C)
Schematic representation of mouse protein Bmcc1 protein
isoforms encoded by the corresponding transcripts shown in B.
Proteins are at scale, with their accession number, size, and library
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indicate that protein may be longer. Conserved domains described
in [36] are indicated on the top of the longest protein, as the
antigenic peptides (asterisks) used to generate the Bmcc1s
antiserum. In comparison to the human sequences presented in
figure S2, Bmcc1 displays an additional exon 7a, generating
specific C-termini in the N-ter proteins. Second, translation of
mouse C-ter Bmcc1 proteins is initiated at the ATG initiation
codon within exon 10, while in human BMCC1 it starts either in
exon 9b or in exon 9c. Consequently, all Bmcc1 C-ter proteins
share the same N-terminus, which differs in human. Finally, exon
7a overlaps the orthologous human PCA3 exon 4 on the opposite
strand, while human PCA3 coding-exons located in intron 6 do
not overlap with BMCC1 exons [36].
(PDF)
Figure S2 Human BMCC1/PRUNE2 gene, transcripts
andproteins. (A) Schematic representation of the BMCC1 gene.
All indicated exons and introns are at scale. Insert at intron 6
indicates the four PCA3 gene exons on the opposite strand. (A,B)
Exons are boxed in black for the coding sequence and in white for
the 59 and 39 non-coding sequences. Alternative start and stop
codons are indicated. B. Schematic representation of human
BMCC1 transcripts. Scale is as in A, and transcripts are given with
their accession number, size, library type, and exon composition.
Dashes indicate still opened reading frames. C. Schematic
representation of human BMCC1 protein isoforms encoded by
the corresponding transcripts shown in B. Proteins are at scale,
with their accession number, size, and library type. Corresponding
coding exons are boxed in light gray. Dashes indicate that protein
may be longer. Bmcc1-1 to Bmcc1-4 are described in [36].
Accession numbers of the partial transcripts (EST) linking exons
1–6 to the remaining exons, or demonstrating the presence of the
ortholog of mouse exon 18 in human transcripts and gene are in
italics. Conserved domains described in [36] are indicated at the
top of the longest protein, as well as the conserved epitope
(asterisk) used to generate Bmcc1 antiserum.
(PDF)
Figure S3 Expression profile of Bmcc1s. RT-PCR using
total RNA extracted from various mouse tissues on the 39 end of
the Bmcc1s 39UTR. Amplification occurred mainly in the brain,
demonstrating that Bmcc1s expression is highly specific to this
organ. Hprt amplification was used as an internal control.
(PDF)
Figure S4 Specificity test of the Bmcc1s antiserum.
Immunoblotting of adult mouse cortex proteins with the Bmcc1s
antiserum (Control), or the antiserum preincubated on sepahrose
bound GST or increasing concentrations of sepharose bound
GST-Bmcc1s. GAPDH expression is shown as a loading reference.
(PDF)
Figure S5 Immunodetection of Bmcc1s in the post-natal
developing brain. Immunoblot of endogenous Bmcc1 isoforms
in mouse brain lysates of post-natal day (P) 1 to 4 months, using
Bmcc1 antiserum. A major 50 kDa band (arrow) corresponding to
Bmcc1s was detected at all stages.
(PDF)
Figure S6 Bmcc1s colocalizes with the neuronal MAP6
isoform N-STOP in primary neurons. Confocal section
images of primary neurons immunostained for Bmcc1s (green) and
N-STOP (red) using the monoclonal antibody 175 [29]. Bar:
10 mm.
(PDF)
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